Help raise awareness of how the FIRST Act will delay public access

Oppose Section 302 of the proposed FIRST Act
A discussion draft of the Frontiers in Innovation, Research, Science and Technology Act of 2013 (FIRST) currently being circulated would impose significant barriers to the public’s ability to access to taxpayer funded research by restricting federal science agencies’ ability to provide timely, equitable, online access to articles and data reporting on the results of research that they support. The proposed FIRST Act is not in the best interests of the taxpayers who fund the research, the scientists who make use of it by accelerating scientific progress, the teachers and students who rely on its availability for a high-quality education, and the thousands of U.S. businesses, both small and large, which depend on public access to stay competitive in the global marketplace. One provision of the bill – Section 302 – would undercut federal agencies’ ability to effectively implement the widely-supported White House Office of Science and Technology Policy Directive on Public Access to the Results of Federally Funded Research, undermine the public access program pioneered by the National Institutes of Health (NIH), and put the U.S. at a severe disadvantage among our global competitors.
SPARC.

‘Open’ as the default modus operandi for research and higher education

is a policy paper by SURF (a collaborative organisation for ICT in Dutch higher education and research) commissioned by the European Commission about open access to content and infrastructure. This was done within the e-InfraNet project. (...) European opinion leaders and experts examined the context, motivations, developments and results of each of the ‘Opens’, revealing a collection of joint benefits and issues. Their study resulted in the recommendation for a coordinated policy approach, able to benefit all forms of ‘Open’.
Download Summary here.  

THE FUTURE OF OPEN KNOWLEDGE: WHAT IMPACT WILL OPEN KNOWLEDGE HAVE ON RESEARCH, THE ECONOMY AND THE PUBLIC?

To mark the launch of the Open Knowledge Foundation in Australia, founder Dr Rufus Pollock is touring Australia. His "Open Knowledge Down Under" tour will take in several capital cities and includes a series of public lectures. The focus of the Sydney lecture will be to talk about the impact of open knowledge on research, the economy and the public. Whilst this is a global initiative, it will include specific focus on the impact in Australia.
Registration is free and open: Monday, 26 August 2013 from 6:00 PM to 7:30 PM (EST), Camperdown, NSW, Auditorium, Eastern Avenue,The University of Sydney.

Open data and open access – what society loses when knowledge is offline

March for public investment and open data

A claim PRO open seed data for better science on nutrition security, sustainability and food systems.

Apotheosis of cynicism and deceit from scholarly publishers

Michael Eisen on the Association of American Publishers’ reaction on the open access movement.

Knowledge exchange – Value of research: Metrics for datasets from a cultural and technical point of view

Mendeley, Open Access, and the Altmetrics Revolution: Implications for Japanese Research

Keita Bando, Mendeley Advisor, Digital Repository Librarian Coordinator for Scholarly Communication, My Open Archive on open access, Mendeley and Altmetrics.

Computational research in the era of open access: Standards and best practices

Ashutosh Jogalekar, a chemist and interested in the history and philosophy of science, proposes on Blogs Scientific American the

The nexus of gov­ern­ment research, reg­u­la­tory agen­cies, uni­ver­sity biol­ogy depart­ments, med­ical schools and drug com­pa­nies

Ethan O. Perlstein hopes that the sci­en­tific com­mu­nity will make big strides toward an open model of drug dis­cov­ery for the ben­e­fit of humankind.

If research is not reproducible then what is the point in publishing?

If research is not reproducible then what is the point in publishing?

Why all pharmaceutical research should be made open access

Why all pharmaceutical research should be made open access

How to act against faked research in China

How to act against faked research in China